agenus

NEWS RELEASE

Agenus to Participate in Rodman & Renshaw Virtual Fireside Chat

2026-11-02

LEXINGTON, Mass.--(BUSINESS WIRE)-- **Agenus Inc.** (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Robin Taylor, Chief Commercial Officer, and Zack Armen, Vice President of Corporate Development and Investor Relations, will participate in a virtual fireside chat hosted by Rodman & Renshaw on Thursday, November 5, 2026.

The discussion will be moderated by Michael G. King, Jr., Senior Biotechnology Analyst and will focus on the development of botensilimab (BOT) and balstilimab (BAL), including neoadjuvant colon cancer results from NEST, UNICORN and NEOASIS, and the planned Phase 3 ROBBIN trial. Management will also discuss strategic priorities, funding and the commercial opportunity for BOT+BAL.

Rodman & Renshaw Virtual Fireside Chat

Date: Thursday, November 5, 2026
Time: 11:30 a.m. to 12:30 p.m. ET
Format: Virtual
Registration: **Register here**

About Agenus

Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Agenus has robust end-to-end development capabilities,

across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit **www.agenusbio.com** or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.

Forward-Looking Statements

This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding its botensilimab and balstilimab programs, expected regulatory timelines and filings, and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "forecasts," "estimates," "will," “establish,” “potential,” “superiority,” “best in class,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K for 2025, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Investors

917-362-1370 | **investor@agenusbio.com**

Media

781-674-4422 | **communications@agenusbio.com**

Source: Agenus Inc.